Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003727 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00003727 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 22 participants.
The verdict
NCT00003727, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with a peripheral stem cell transplant and immunotherapy may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: This phase II trial is studying giving chemotherapy together with a peripheral stem cell transplant followed by immunotherapy to see how well it works in treating patients with chronic phase chronic myelogenous leukemia.
Interventions
- DRUG carmustine
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL filgrastim
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL sargramostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 1999-03 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003727
The ClinicalTrials.gov registry entry for NCT00003727 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carmustine is the first listed.
NCT00003727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003727 about?
NCT00003727 is a clinical study titled "Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with a peripheral stem cell transplant and immunotherapy may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Biologi...
What is the current status of trial NCT00003727?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 1999-03. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00003727?
The interventions under investigation include: carmustine (DRUG), therapeutic autologous lymphocytes (BIOLOGICAL), filgrastim (BIOLOGICAL), recombinant interferon alfa (BIOLOGICAL), sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003727?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.